Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

NCT04911517 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

COMBINATION_PRODUCT: long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

Sponsor

Beijing Friendship Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]